Filing Flows › Cartesian Therapeutics (RNAC) › Stock forecast & fair value
Cartesian Therapeutics (RNAC) stock forecast and price target
Cartesian Therapeutics (RNAC) trades at $7.53. 6 analysts' median price target is $38.50 (+411%), from $16.00 to $44.00.
Cartesian Therapeutics' latest quarter
Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for RNAC stock?
The median of 6 analysts' 12-month targets is $38.50, +411% from $7.53; the range is $16.00 to $44.00. The average rating is none.
Does Cartesian Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 20% of the quarters on record.
Is RNAC stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.